Comparison of WT1 mRNA response and clinical outcome. (A) Comparison of mPFS and the ratio of week-0 to week-10 WT1 mRNA levels in BM. (B) Comparison of PFS and the ratio of week-0 to week-10 WT1 mRNA levels in BM. ♦ indicates patients with high blasts in BM at baseline; and , patients with low blasts in BM at baseline. *The 2 patients still on treatment with ongoing SD.